Spikevax (Original/ Omicron) COVID-19 Vaccine: What Moderna’s mRNA Shot Offers US Patients

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 4:18 PM ET. Details in the imprint.

Spikevax (Original/Omicron) is Moderna’s updated mRNA COVID-19 vaccine, designed to protect against both the ancestral SARS-CoV-2 strain and circulating Omicron-lineage variants, and it remains a key option for US patients seeking booster protection. The product is authorized in the United States with age-tailored formulations and is distributed widely through retail pharmacies, clinics and healthcare providers. For consumers, the main decision points are eligibility, dosing schedule and access, rather than having to decode complex scientific terminology.

What Spikevax (Original/Omicron) is designed to do

Spikevax (Original/Omicron) is an mRNA-based vaccine: it contains messenger RNA encoding the spike protein of SARS-CoV-2, including sequences adapted to Omicron-lineage variants such as XBB, to trigger an immune response without using live virus. Once injected, the lipid nanoparticle formulation delivers this mRNA into cells, which briefly produce spike protein fragments that the immune system learns to recognize, training both antibody and T-cell responses. The vaccine is indicated as a primary series and booster in specific age groups, depending on current US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) guidance.

Regulators and public-health experts have increasingly emphasized updated COVID-19 vaccines that match currently circulating variants, and Moderna has adapted Spikevax to meet those recommendations. In fall 2023, the FDA approved an updated monovalent XBB.1.5 formulation of Spikevax for individuals 12 years and older, and authorized it under emergency use for children 6 months through 11 years, aligning with CDC advisory committee recommendations for the 2023-2024 respiratory virus season. That XBB.1.5-targeting product is generally referred to in consumer materials as Spikevax (Original/Omicron) or Spikevax (XBB.1.5), depending on jurisdiction and labeling.

Clinical data submitted to regulators showed that the XBB.1.5-adapted Spikevax generated neutralizing antibody responses against XBB-lineage Omicron variants that were at least non-inferior, and in some analyses superior, to the prior bivalent formulation, while maintaining a safety profile consistent with earlier versions. The most common adverse reactions remain short-lived and include injection-site pain, fatigue, headache, muscle aches, joint pain, chills and fever; these typically resolve within a few days. Rare cases of myocarditis and pericarditis have been observed, primarily in adolescent and young adult males, a risk that regulators and professional societies highlight in their guidance while still recommending vaccination for most eligible individuals.

Dosage, age groups and how US patients get the vaccine

For most people in the United States, Spikevax (Original/Omicron) is given as a single 0.5 mL intramuscular dose in the upper arm, using a multidose vial prepared according to the package instructions. Adults and adolescents 12 years of age and older who have not yet received an updated XBB-lineage COVID-19 vaccine are generally eligible for one dose, while young children have age-specific dosing and multi-dose primary schedules. For example, children 6 months through 4 years typically receive smaller-volume doses and may require multiple injections to complete an age-appropriate series, depending on their prior COVID-19 vaccination history.

Spikevax (Original/Omicron) is available across major US pharmacy chains such as CVS and Walgreens, through hospital systems, local clinics and community health centers, often by appointment but in many locations on a walk-in basis. The vaccine is supplied in cartons of single multidose vials that must be stored frozen and then refrigerated before use, following detailed cold-chain requirements specified by Moderna and regulators. These storage and handling rules matter for providers rather than patients, but they help explain why doses are concentrated at locations with appropriate freezer capacity and trained staff.

Pricing for Spikevax in the US commercial market was set in the mid-$100s per dose when the product transitioned from federal government purchasing to private distribution after the end of the national public-health emergency. However, out-of-pocket costs for most insured Americans are expected to be minimal, because public and private payers generally cover recommended vaccines, including updated COVID-19 shots, with no copay when administered by in-network providers. For the uninsured or underinsured, programs such as the federal Bridge Access Program and manufacturer assistance initiatives aim to provide no-cost or low-cost access at participating sites.

How Spikevax (Original/Omicron) fits into Moderna’s vaccine portfolio

Spikevax (Original/Omicron) remains Moderna’s best-known commercial product and was the company’s first fully approved vaccine in the United States, supported by large phase 3 trials that began with the original mRNA-1273 formulation. The company has since expanded its respiratory portfolio with late-stage candidates targeting influenza and respiratory syncytial virus (RSV), and regulators are actively reviewing Moderna’s mRNA influenza vaccine for adults 50 and older. In the long term, Moderna has stated in investor presentations that it aims to build combination respiratory vaccines, such as a single shot protecting against influenza, COVID-19 and RSV, which would logically build on the platform experience gained with Spikevax.

From a technology standpoint, Spikevax (Original/Omicron) illustrates Moderna’s core approach: rapidly updating an mRNA construct and manufacturing process to respond to evolving viral variants, then scaling production in collaboration with contract manufacturing organizations and in-house facilities. According to company disclosures, the same mRNA platform is being used for a broad pipeline, including vaccines for cytomegalovirus (CMV), HIV, and emerging pathogens supported by organizations like the Coalition for Epidemic Preparedness Innovations (CEPI). Investors and healthcare professionals often look at Spikevax as both a revenue driver in its own right and as a proof-of-concept for the wider mRNA pipeline.

Regulatory and public-health guidance around updated COVID-19 vaccination is evolving as new data emerge on variant circulation, durability of protection and hybrid immunity from infection and prior doses. Professional bodies such as the Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG) now integrate updated COVID-19 vaccines, including Spikevax, into seasonal respiratory vaccine schedules, especially for older adults, pregnant individuals and those with underlying conditions. For consumers watching the product, the most practical step is to check current CDC recommendations and local availability, since eligibility criteria and timing of booster doses can change from season to season.

Spikevax is strategically central to Moderna’s transition from a single-product COVID-19 company toward a broader vaccines and therapeutics business, providing both cash flow and clinical experience that support newer programs. Shares of Moderna Inc. (US60770K1079, ticker MRNA) traded at $118.40 on Nasdaq on June 11, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.

en | US60770K1079 | MRNA | boerse | 69528167 | bgmi